Takeda Pharmaceutical Company Limited

4502

JP3463000004

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-19 am EDT			5-day change	1st Jan Change
4,069 ^JPY	-0.49%		-1.86%	+0.37%

10:21am	Takeda Pharmaceutical Receives FDA Approval for Single-Dose Injection Crohn's Disease Treatment	MT
Apr. 18	Takeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's Disease	DJ

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Year Ending March 31, 2021

July 30, 2021 at 02:00 am EDT

Takeda Pharmaceutical Company Limited provided earnings guidance for the year ending March 31, 2021. For the period, the company expects revenue of ¥3,370,000 million, Operating profit of ¥488,000 million, Net profit attributable to owners of the company of ¥250,000 million or ¥159.91 basic per share.

Latest news about Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Receives FDA Approval for Single-Dose Injection Crohn's Disease Treatment	04:21am	MT
Takeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's Disease	Apr. 18	DJ
Takeda Pharmaceutical to Issue 2nd Hybrid Bonds in Mid-2024 to Refinance 500 Billion Yen 1st Hybrid Bonds	Apr. 15	MT
Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited.	Mar. 31	CI
Takeda Pharmaceutical Says Adzynma Gains Approval in Japan to Treat Blood Clotting Disorder	Mar. 26	MT
Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura	Mar. 26	CI
Scilex Settles Patent Dispute With Takeda Pharmaceutical Over Gloperba	Mar. 20	MT
Takeda Pharmaceutical Receives FDA Approval to Expand Iclusig's Indication in Blood Cancer Sub-Type	Mar. 19	MT
Centogene, Takeda Pharmaceutical Collaborate on Lysosomal Storage Disorders Diagnostics	Mar. 19	MT
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® in Adult Patients with Newly Diagnosed Ph+ ALL	Mar. 19	CI
Takeda Pharmaceutical Says Mezagitamab Phase 2 Trial Shows 'Positive' Results in Primary Immune Thrombocytopenia Patients	Mar. 13	MT
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia	Mar. 13	CI
Toyota becomes Asia's most shorted large-cap stock - Hazeltree	Mar. 12	RE
India's Serum looks beyond COVID with new vaccines for malaria, dengue	Mar. 10	RE
EARNINGS: Hutchmed revenue surges, Craven House's loss widens	Feb. 28	AN
Takeda Pharmaceutical Teams Up With Biological E. to Boost Production of Dengue Vaccine	Feb. 27	MT
HEDGEFLOW - Japan enthusiasm driving inflows to US-listed Asian equities, Morgan Stanley says	Feb. 27	RE
Japan's Takeda partners with India's Biological E. to boost dengue vaccine production	Feb. 27	RE
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas	Feb. 26	CI
Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,600 Yen From 5,200 Yen, Keeps at Buy	Feb. 13	MT
Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited	Feb. 13	CI
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	Feb. 12	MT
Takeda Pharmaceutical Says US FDA Approves Eohilia as Eosinophilic Esophagitis Treatment	Feb. 12	MT
US FDA approves Takeda's therapy for allergic inflammation in esophagus	Feb. 12	RE
FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)	Feb. 12	CI

Chart Takeda Pharmaceutical Company Limited

Duration

Period

Chart Takeda Pharmaceutical Company Limited

More charts

Company Profile

Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - services. Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).

Sector

Pharmaceuticals

Calendar

2024-05-09 - Q4 2023 Earnings Release

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Takeda Pharmaceutical Company Limited

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4,089 JPY

Average target price

4,790 JPY

Spread / Average Target

+17.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TAKEDA PHARMACEUTICAL COMPANY LIMITED	+0.37%	41.5B
ELI LILLY AND COMPANY	+27.97%	672B
NOVO NORDISK A/S	+23.35%	550B
JOHNSON & JOHNSON	-7.02%	351B
MERCK & CO., INC.	+14.85%	317B
ABBVIE INC.	+6.25%	292B
ASTRAZENECA PLC	+1.57%	211B
NOVARTIS AG	-0.72%	203B
ROCHE HOLDING AG	-10.51%	194B
PFIZER, INC.	-11.81%	144B

Other Pharmaceuticals